About This Overview
This page summarizes the published clinical research on Boswellia serrata across all health indications where trials have been conducted. Evidence grades reflect the quality, consistency, and volume of clinical trial evidence — not the magnitude of claimed effects. Grades are assigned conservatively.
Osteoarthritis (Knee)
Moderate — Best-Supported
The most extensively studied indication. Multiple RCTs and a 2020 meta-analysis (n=545) have reported statistically significant differences in pain and function scores versus placebo. The majority of trials are industry-funded and of short duration (8–12 weeks). Effect sizes are modest; clinical significance is uncertain. Independent replication is limited. → Full osteoarthritis evidence summary
Inflammatory Bowel Disease
Mixed / Limited
Small trials in ulcerative colitis and Crohn's disease have produced inconsistent results. An early UC trial reported favorable outcomes; a larger, adequately powered Crohn's remission trial reported null results. Sample sizes are small and extract standardization varies across studies. → Full IBD evidence summary
Bronchial Asthma
Limited
One reasonably designed RCT (n=80) reported statistically significant improvements in symptom scores and lung function versus placebo over 6 weeks. The trial has not been independently replicated and predates modern asthma trial methodology. → Full respiratory evidence summary
Brain Health and Cognition
Preliminary
Research is primarily from animal models examining incensole acetate. No adequately powered RCT has been published for any cognitive or neurological outcome. → Full brain health evidence summary
Skin Health
Insufficient
No controlled clinical trials have been published in any dermatological indication. Available data is limited to in vitro studies and anecdotal reports. → Full skin health evidence summary
Inflammatory Pathways — Mechanistic
Mechanistic Only
Substantial in vitro and animal model data demonstrates AKBA's inhibition of 5-LOX and possible modulation of NF-κB and MMP pathways. These are mechanistic findings only and do not establish clinical outcomes. → Full mechanistic evidence summary
Across all indications, the boswellia clinical trial literature is characterized by small sample sizes, predominantly industry-funded trials, short trial durations, and limited independent replication. These systemic limitations affect confidence in findings across the board.